http://www.businessinsider.com/allergan-q2-results-2014-7
Allergan is currently fending off a takeover bid from Valeant and activist investor Bill Ackman, which this morning announced
that it contracted the SEC and regulatory authorities in Canada
regarding, "Allergan's apparent attempt to mislead investors and
manipulate the market for Valeant common shares by continuing to make
false and misleading statements regarding Valeant's business despite
Valeant's public statements correcting such information."
No comments:
Post a Comment